Çınar 2020.

Study characteristics
Methods	Trial design: case report Type of publication: journal publication Setting: hospital Recruitment dates: NR Country: Turkey Language: English Number of centres: 1 Trial registration number: NR Date of registration: NR
Participants	Age: 55 Gender: male Ethnicity: NR Number of participants (recruited/allocated/evaluated): 1 Severity of disease: moderate to critical Co‐morbidities: myelodysplasia, disseminated systemic tuberculosis infection and kidney disease Inclusion criteria: NR Exclusion criteria: NR Previous treatments (e.g. experimental drug therapies, oxygen therapy, ventilation): an antiviral drug (favipiravir), meropenem, tocilizumab, 4‐drug regimen for tuberculosis, low‐flow oxygen
Interventions	CP therapy or hyperimmune immunoglobulin therapy: CP therapy Details of CP: Type of plasma: collected using Trima Accel®Automated Blood Collection Systemfrom a donor who had previously recovered from COVID‐19 disease and met universal donation criteria. Volume: 200 mL each dose Number of doses: 2 Antibody test and antibody‐titre: anti‐SARS‐CoV‐2 IgG semi‐quantitative titre of the donor’s plasma studied by the EUROIMMUN ELISAkit (order no EI 2606‐9601 G. Produced by EUROIMMUN AG, Seekamp31, 23560 Lübeck, Germany) was positive (Titer 6.6; < 0.8 negative, ≥ 0.8 to < 1.1 borderline, ≥ 1.1 positive)  Pathogen inactivated or not: NR RT‐PCR tested: NR Details of donors: Gender: NR HLA and HNA antibody‐negative: NR Severity of disease: NR Timing from recovery from disease: NR RT‐PCR tested: NR Treatment details, including time of plasma therapy (e.g. early stage of disease): administered between 1 and 3 days after admission For studies including a control group: comparator (type): not applicable Concomitant therapy: an antiviral drug (favipiravir), meropenem, tocilizumab, 4‐drug regimen for tuberculosis, low‐flow oxygen Duration of follow‐up: up to 11 days Treatment cross‐overs: not applicable Compliance with assigned treatment: not applicable
Outcomes	Primary study outcome(s): NR Primary review outcomes All‐cause mortality at hospital discharge: reported Time to death: not applicable Secondary review outcomes Number of participants with grade 3 and grade 4 AEs, including potential relationship between intervention and adverse reaction (e.g. TRALI, transfusion‐transmitted infection, TACO, TAD, acute transfusion reactions): NR Number of participants with SAEs: NR Improvement of clinical symptoms, assessed through need for respiratory support at up to 7 days; 8‐15 days; 16‐30 days: reported 30‐day and 90‐day mortality: not applicable Admission on the ICU: reported Length of stay on the ICU: reported Time to discharge from hospital: reported QoL: NR Additional study outcomes: NR
Notes	Sponsor/funding: no funding received COIs: all study authors declare no competing interests Other: nil

AE: adverse event; ALT: alanine aminotransferase; ARDS: acute respiratory distress syndrome; AST: aspartate transaminase; COI: conflict of interest; COPD: chronic obstructive pulmonary disease; CP: convalescent plasma; CPAP: continuous positive airway pressure; CPK: creatine phosphokinase; CRP: C‐reactive protein; CT: computed tomography; ECMO: extracorporeal membrane oxygenation; ELISA: enzyme‐linked immunosorbent assay; FiO2: fractional inspired oxygen; GI: gastrointestinal; HBV/HCV: hepatitis B/C; HLA: human leukocyte antigen; HNA: human neutrophil antigen; ICU: intensive care unit; IgA (B/G/M): immunoglobulin A (B/G/M); IL‐6: interleukin‐6; IQR: interquartile range; IRB: Institutional Review Board; IV: intravenous; IVIG: intravenous immunoglobulin; LDH: lactate dehydrogenase; MODS: multiple organ dysfunction syndrome; NR: not reported; OD: optical density; OSA: obstructive sleep apnoea; PaO2: arterial blood oxygen partial pressure; PCR: polymerase chain reaction; QoL: quality of life; RBD: receptor binding domain; RCT: randomised controlled trial; RNA: ribonucleic acid; RT‐PCR: reverse transcription polymerase chain reaction; SAE: serious adverse event; SARS: severe acute respiratory syndrome; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; TACO: transfusion‐associated circulatory overload; TAD: transfusion‐associated dyspnoea; TRALI: transfusion‐related acute lung injury